In addition, anti-epithelial growth factor receptor (EGFR) antibodies such as cetuximab [9] and immune checkpoint inhibitors such as nivolumab [9, 10] and pembrolizumab [12–15] have been introduced as novel agents against oral cancer, which contribute to improved survival rates. This evidence concerns the gene EGFR and lip and oral cavity carcinoma.